Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Journal of Virology

Volumn 86, Issue 21, 2012, Pages 11521-11532

  Bonsignori, Mattia ^a   Pollara, Justin ^a   Moody, Anthony ^a   Chen, Xi ^a   Hwang, Kwan Ki ^a   Gurley, Thaddeus C ^a   Kozink, Daniel M ^a   Marshall, Dawn J ^a   Whitesides, John F ^a   Tsao, Chun Yen ^a   Tomaras, Georgia D ^a   Montefiori, David C ^a   Ferrari, Guido ^a   Liao, Hua Xin ^a   Haynes, Barton F ^a   Alpert, Michael D ^b   Evans, David T ^b   Gilbert, Peter B ^c   Huang, Ying ^c   Kaewkungwal, Jaranit ^d   Nitayaphan, Sorachai ^e   Pitisuttithum, Punnee ^d   Rerks Ngarm, Supachai ^f   Kim, Jerome H ^g   Michael, Nelson L ^g   Lewis, George K ^h   DeVico, Anthony ^h   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g US Military HIV Research Program   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PLACEBO;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL KILLING; CELL MATURATION; CELL SELECTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT RESPONSE; VACCINATION; VH1 GENE; VIRUS GENE;

AIDS VACCINES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HIV ANTIBODIES; HIV-1; HUMAN EXPERIMENTATION; HUMANS; MALE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84867902474     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01023-12     Document Type: Article

References (54)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Barouch DH, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
3. Baum LL, et al. 1996. HIV-1 gp120-specific antibody-dependent cellmediated cytotoxicity correlates with rate of disease progression. J. Immunol.157:2168-2173.
4. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
5. Breden F, et al. 2011. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 6:e16857. doi:10.1371/journal.pone.0016857.
6. Brezinschek HP, Brezinschek RI, Lipsky PE. 1995. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 155:190-202.
7. Brocca-Cofano E, et al. 2011. Vaccine-elicited SIV and HIV envelopespecific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 29:3310-3319.
8. Burton DR, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U.S.A.108:11181-11186.
9. DeVico A, et al. 2007. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U.S.A. 104:17477-17482.
10. Edmonds TG, et al. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13.
11. Ewing B, Green P. 1998. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 8:186-194.
12. Ewing B, Hillier L, Wendl MC, Green P. 1998. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 8:175-185.
13. Ferrari G, et al. 2011. A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent ADCC activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85:7029-7036.
14. Florese RH, et al. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol.182:3718-3727.
15. Gómez-Román VR, et al. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reducedacute viremia in rhesus macaques challenged with SIVmac251. J.Immunol. 174:2185-2189.
16. Gray ES, et al. 2011. Isolation of a monoclonal antibody targeting the alpha-2 helix of gp120 representing the initial autologous neutralizing antibody response in an HIV-1 subtype C infected individual. J. Virol. 85:7719-7729.
17. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
18. Hidajat R, et al. 2009. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83:791-801.
19. Johnson S, et al. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
20. Kabat EA, Wu TT, Perry MH, Gottesman KS, Foeller C. 1991. Sequences of proteins of immunological interest, 5th ed. U.S. Department of Health and Human Services, Bethesda, MD.
21. Karnasuta C, et al. 2005. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-2529.
22. Lambotte O, et al. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.AIDS 23:897-906.
23. Liao HX, et al. 2012. HIV-1 envelope antibodies induced by ALVACAIDSVAX B/E vaccine target a site of vaccine immune pressure within the C β-strand of gp120 V1/V2, abstr 230, p 110. Keystone Symp. HIV Vaccines.
24. Liao HX, et al. 2011. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208:2237-2249.
25. Liao HX, et al. 2009. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.J. Virol. Methods 158:171-179.
26. Ljunggren K, et al. 1990. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J. Infect. Dis. 161:198-202.
27. Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251. doi:10.1371/journal.ppat.1001251.
28. Montefiori DC, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect.Dis. 206:431-441.
29. Moody MA, et al. 2012. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 86:7496-7507.
30. Moody MA, et al. 2011. H3N2 influenza infection elicits more crossreactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 6:e25797. doi:10.1371/journal.pone.0025797.
31. Moore JP, et al. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
32. Munshaw S, Kepler TB. 2010. SoDA2: a Hidden Markov Model approach for identification of immunoglobulin rearrangements. Bioinformatics 26:867-872.
33. Nag P, et al. 2004. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect.Dis. 190:1970-1978.
34. Nitayaphan S, et al. 2004. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J.Infect. Dis. 190:702-706.
35. O'Doherty U, Swiggard WJ, Malim MH. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.J. Virol. 74:10074-10080.
36. Pollara J, et al. 2011. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79:603-612.
37. Pollara J, et al. 2010. Early appearance of ADCC- and ADCVI-mediating antibody responses against autologous HIV-1 transmitted/founder virus.AIDS Res. Hum. Retrovir. 26:A-12.
38. Pollara J, et al. 2011. Ontogeny, breadth and specificity of circulating ADCC-mediating antibodies in HIV-1 infected individuals. AIDS Res. Hum. Retroviruses 27:A-66.
39. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209 -2220.
40. Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES. 2005.High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Hum. Antibodies 14:115-121.
41. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
42. Shen X, et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83:3617-3625.
43. Shields RL, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J.Biol. Chem. 276:6591-6604.
44. Smith TF, Waterman MS. 1981. Identification of common molecular subsequences. J. Mol. Biol. 147:195-197.
45. Sun Y, et al. 2011. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85:6906-6912.
46. Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
47. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. 1999. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J.Virol. 73:8966-8974.
48. Volpe JM, Cowell LG, Kepler TB. 2006. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations.Bioinformatics 22:438-444.
49. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc.Natl. Acad. Sci. U.S.A. 108:14216 -14221.
50. Wrammert J, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671.
51. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
52. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
53. Wyatt R, et al. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
54. Yagita M, et al. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922-930.